IP Library › Granted Patent US 11,524,998

Granted Patent B2

US 11,524,998 · App. 17/375,860 · Granted Dec 13, 2022

Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules

Inventors: Chad Eric Bigelow (Somerville, MA); Ana Maria Carrion (Wellesley, MA); James Edgar Chastain (Acton, MA); Kirk Lee Clark (Stow, MA); Bijan Alexandre Etemad-Gilbertson (Jamaica Plain, MA); Joy Gispati Ghosh (Boston, MA); Shawn Michael Hanks (Sudbury, MA); Nicole Haubst (Munich, DE); Ganesh Rajan Iyer (South Grafton, MA); Nina Moker (Cologne, DE); Andrew Anh Nguyen (Brookline, MA); Stephen Hedrick Poor (Winthrop, MA); Yubin Qiu (Newton, MA); Nalini Velamur Rangaswamy (Wakefield, MA); Michael Stefanidakis (Brookline, MA); Engin Toksoz (Munich, DE); Michael Zbigniew Twarog (Cambridge, MA)

Assignee: NOVARTIS AG

C07K16/22 A61P27/02 C07K16/468 A61K2039/507 A61K2039/545 C07K2317/31 C07K2317/55 C07K2317/565 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 11,524,998
App. No.: 17/375,860
Granted: Dec 13, 2022
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.

Claims (62)

1. A multi-specific binding molecule comprising 1) an anti-betacellulin (BTC) binding moiety and 2) an anti-vascular endothelial growth factor (VEGF) binding moiety, wherein the anti-BTC binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 as set forth in:

a. SEQ ID NOs: 1, 2, 3, 14, 15, and 16, respectively; SEQ ID NOs: 4, 2, 3, 14, 15, and 16, respectively; SEQ ID NOs: 5, 6, 3, 17, 18, and 19, respectively; or SEQ ID NOs: 7, 8, 9, 20, 18, and 16, respectively;

b. SEQ ID NOs: 25, 26, 27, 38, 39, and 40, respectively; SEQ ID NOs: 28, 26, 27, 38, 39, and 40, respectively; SEQ ID NOs: 29, 30, 27, 41, 42, and 43, respectively; or SEQ ID NOs: 31, 32, 33, 44, 42, and 40, respectively;

c. SEQ ID NOs: 25, 49, 50, 58, 59, and 60, respectively; SEQ ID NOs: 28, 49, 50, 58, 59, and 60, respectively; SEQ ID NOs: 29, 51, 50, 61, 62, and 63, respectively; or SEQ ID NOs: 31, 52, 53, 64, 62, and 60, respectively; or

d. SEQ ID NOs: 69, 70, 71, 82, 83, and 84, respectively; SEQ ID NOs: 72, 70, 71, 82, 83, and 84, respectively; SEQ ID NOs: 73, 74, 71, 85, 18, and 86, respectively; or SEQ ID NOs: 75, 76, 77, 87, 18, and 84, respectively,

wherein the anti-BTC binding moiety and the anti-VEGF binding moiety are an antibody or antigen binding fragment thereof.

2. The multi-specific binding molecule of claim 1 , wherein the anti-VEGF binding moiety is an anti-VEGF antibody or antigen binding fragment thereof in a format selected from the group consisting of an isolated antibody, a Fab, a Fab′, a F(ab′) 2 , a Fv, and a scFv.

3. The multi-specific binding molecule of claim 1 , wherein the anti-BTC binding moiety is an anti-BTC Fab and the anti-VEGF binding moiety is an anti-VEGF Fab, wherein the anti-BTC Fab comprises a heavy chain (HA) and a light chain (LA), and wherein the anti-VEGF Fab comprises a heavy chain (HB) and a light chain (LB).

4. The multi-specific binding molecule of claim 3 , wherein the HA and the HB are linked in the format from the N-terminus to the C-terminus: N-HA-linker 1-HB-C, and wherein the LA and the LB are linked in the format from the N-terminus to the C-terminus: N-LA-linker 2-LB-C.

5. The multi-specific binding molecule of claim 1 , wherein the anti-BTC binding moiety comprises a VH and a VL comprising an amino acid sequence with at least 90% sequence identity to:

a. SEQ ID NOs: 10 and 21, respectively;

b. SEQ ID NOs: 34 and 45, respectively;

c. SEQ ID NOs: 54 and 65, respectively; or

d. SEQ ID NOs: 78 and 88, respectively.

6. The multi-specific binding molecule of claim 5 , wherein the anti-BTC binding moiety comprises a heavy chain and a light chain with an amino acid sequence as set forth in:

a. SEQ ID NOs: 12 and 23, respectively;

b. SEQ ID NOs: 36 and 47, respectively;

c. SEQ ID NOs: 56 and 67, respectively; or

d. SEQ ID NOs: 80 and 90, respectively.

7. The multi-specific binding molecule of claim 1 , wherein the anti-VEGF binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 as set forth in:

a. SEQ ID NOs: 92, 93, 94, 105, 106, and 107 respectively;

b. SEQ ID NOs: 95, 93, 94, 105, 106, and 107, respectively;

c. SEQ ID NOs: 96, 97, 94, 108, 109, and 110, respectively; or

d. SEQ ID NOs: 98, 99, 100, 111, 109, and 107, respectively.

8. The multi-specific binding molecule of claim 7 , wherein the anti-VEGF binding moiety comprises a VH and VL comprising an amino acid sequence with at least 90% sequence identity to SEQ ID NOs: 101 and 112, respectively.

9. The multi-specific binding molecule of claim 7 , wherein the anti-VEGF binding moiety comprises a VH and VL encoded by the nucleic acid sequence as set forth in:

a. SEQ ID NOs: 102 and 113, respectively;

b. SEQ ID NOs: 117 and 123, respectively;

c. SEQ ID NOs: 128 and 133, respectively;

d. SEQ ID NOs: 138 and 143, respectively; or

e. SEQ ID NOs: 148 and 152, respectively.

10. The multi-specific binding molecule of claim 7 , wherein the anti-VEGF binding moiety comprises a heavy chain and a light chain with the amino acid sequence as set forth in SEQ ID NOs: 103 and 114, respectively, or wherein the heavy chain and light chain are encoded by a nucleic acid sequence with 100% sequence identity to SEQ ID NOs: 104 and 115, respectively.

11. The multi-specific binding molecule of claim 1 , wherein the anti-BTC binding moiety comprises a variable heavy chain domain (VHA) and a variable light chain domain (VLA) that bind to BTC, and wherein the anti-VEGF binding moiety comprises a variable heavy chain domain (VHB) and a variable light chain domain (VLB) that bind to VEGF, wherein the multi-specific binding molecule is in the format from the N-terminus to C-terminus as: N-VHA-heavy chain constant domain (CH1A)-linker 1-VHB-heavy chain constant domain (CH1B)-C and N-VLA-light chain constant domain (CKA)-linker 2-VLB-light chain constant domain (CKB)-C, which comprises a heavy chain comprising the VHA, CH1A, linker 1, VHB, and CH1B, and which comprises a light chain comprising the VLA, CKA, linker 2, VLB, and CKB, wherein the heavy chain and the light chain is as set forth in:

a. SEQ ID NOs: 120 and 125, respectively;

b. SEQ ID NOs: 130 and 135, respectively;

c. SEQ ID NOs: 140 and 145, respectively; or

d. SEQ ID NOs: 149 and 154, respectively.

12. The multi-specific binding molecule of claim 1 , wherein the anti-BTC binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 and the anti-VEGF binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, which are as set forth in:

a. SEQ ID NOs: 1, 2, 3, 14, 15, 16, 92, 93, 94, 105, 106, and 107, respectively;

b. SEQ ID NOs: 4, 2, 3, 14, 15, 16, 95, 93, 94, 105, 106, and 107, respectively;

c. SEQ ID NOs: 5, 6, 3, 17, 18, 19, 96, 97, 94, 108, 109, and 110, respectively; or

d. SEQ ID NOs: 7, 8, 9, 20, 18, 16, 98, 99, 100, 111, 109, and 107, respectively.

13. The multi-specific binding molecule of claim 1 , wherein the anti-BTC binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 and the anti-VEGF binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, which are as set forth in:

a. SEQ ID NOs: 25, 26, 27, 38, 39, 40, 92, 93, 94, 105, 106, and 107, respectively;

b. SEQ ID NOs: 28, 26, 27, 38, 39, 40, 95, 93, 94, 105, 106, and 107, respectively;

c. SEQ ID NOs: 29, 30, 27, 41, 42, 43, 96, 97, 94, 108, 109, and 110, respectively; or

d. SEQ ID NOs: 31, 32, 33, 44, 42, 40, 98, 99, 100, 111, 109, and 107, respectively.

14. The multi-specific binding molecule of claim 1 , wherein the anti-BTC binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 and the anti-VEGF binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, which are as set forth in:

a. SEQ ID NOs: 25, 49, 50, 58, 59, 60, 92, 93, 94, 105, 106, and 107, respectively;

b. SEQ ID NOs: 28, 49, 50, 58, 59, 60, 95, 93, 94, 105, 106, and 107, respectively;

c. SEQ ID NOs: 29, 51, 50, 61, 62, 63, 96, 97, 94, 108, 109, and 110, respectively; or

d. SEQ ID NOs: 31, 52, 53, 64, 62, 60, 98, 99, 100, 111, 109, and 107, respectively.

15. The multi-specific binding molecule of claim 1 , wherein the anti-BTC binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 and the anti-VEGF binding moiety comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, which are as set forth in:

a. SEQ ID NOs: 69, 70, 71, 82, 83, 84, 92, 93, 94, 105, 106, and 107, respectively;

b. SEQ ID NOs: 72, 70, 71, 82, 83, 84, 95, 93, 94, 105, 106, and 107, respectively;

c. SEQ ID NOs: 73, 74, 71, 85, 18, 86, 96, 97, 94, 108, 109, and 110, respectively; or

d. SEQ ID NOs: 75, 76, 77, 87, 18, 84, 98, 99, 100, 111, 109, and 107, respectively.

16. A polynucleotide comprising a nucleotide sequence encoding the anti-BTC binding moiety of the multi-specific binding molecule of claim 1 .

17. An expression cassette or a vector comprising the polynucleotide of claim 16 .

18. A pharmaceutical composition comprising an effective amount of the multi-specific binding molecule of claim 1 .

19. A kit comprising the pharmaceutical composition of claim 18 .

20. A polynucleotide comprising a nucleotide sequence encoding the multi-specific binding molecule of claim 11 .

Assignments (16)